

Haemonetics Corporation

JP Morgan 41st Annual Healthcare Conference

January 10, 2023

Important Information

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “foresees,” “potential” and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation (the “Company”), including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the impact of the COVID-19 pandemic on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company’s most recent Annual Report on Form 10-K under the headings “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” and in the Company’s other periodic filings with the U.S. Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements..

Non-GAAP Financial Measures

This presentation includes estimates of future financial performance that are based on non-GAAP financial measures as defined under applicable SEC rules and regulations. Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. Descriptions of non-GAAP measures referenced in this presentation are available on our website at www.haemonetics.com. The Company does not provide a reconciliation of forward-looking non-GAAP measures referenced in this presentation because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts. Estimates of future financial performance in this presentation represent the Company’s long-term goals and are not intended as guidance. See “Safe Harbor for Forward-Looking Statements” above regarding forward-looking statements made in this presentation.

Not a Recommendation of any Security

This presentation provides an overview of the Company and is not intended to be taken by, and should not be taken by, any individual recipient as a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.


Haemonetics – Key Accomplishments Since IR Day



Fueling recovery in plasma collection volumes



Driving expansion of our Hospital business



Providing an uninterrupted supply of our products



Accomplishing key growth and competitive milestones across our businesses



Advancing high-impact R&D and regulatory initiatives



Achieving cost savings and helping reduce economic pressures through the Operational Excellence Program

FY'23 - FY'26: Transformational Growth

CORPORATE STRATEGY

Compete in winning segments and geographies

Achieve leading positions

Deliver superior operating performance

GOALS

► GROWTH



Revenue



Profitability



Cash Flow

► DIVERSIFICATION

- Business Segments
- Customers
- Geographies
- Business Models

► SUSTAINABILITY

- Economic
- People
- Societal
- Environmental

Robust Shareholder Value Creation Model

SUSTAINABLE GROWTH

HIGH SINGLE DIGIT
organic revenue CAGR

MID TEENS
CAGR in adjusted diluted EPS

INCREASING PROFITABILITY

HIGH TEENS
CAGR in adjusted operating income

HIGH TWENTIES
adjusted operating income margin in FY'26

CAPITAL ALLOCATION

\$0.6B TO \$0.7B
of cumulative FCF¹ FY'23 - FY'26

UP TO \$2.1B
in capital capacity² to support a disciplined capital allocation strategy


1) Free cash flow after restructuring and restructuring-related costs. 2) Capital capacity by the end of FY'26.

Value Drivers Support Transformational Growth



Plasma

Supporting volume recovery via further improvements in yield, efficiency, compliance and donor safety to drive donor satisfaction and lower costs per liter



Hospital

Unlocking market potential and accelerating growth and TAM with innovative products and expansion across existing customers and new markets worldwide



Innovation Agenda

Concentrating in high-growth segments; advancing the standards of care and lowering the costs of care through product and platform innovation supported by clinical evidence



Inorganic Growth

Using M&A to strengthen leadership position in core and adjacent markets; focusing on unique value-adding products and superior ROI



Operational Excellence

Improving product quality, agility and resiliency, while creating savings to free up resources for investments in growth



Resource Allocation


Focusing on targeted investments in organic and inorganic growth, while rewarding shareholders

Plasma Drives Sustainable Growth and Margin Expansion

Market

- ~\$800M TAM¹ growing 8-10%
- Covid-19 creates the need for a robust recovery and increased collections efficiency

U.S. Source Plasma Market^{1,2}



Technology

NexSys® platform improves plasma volume and reduces cost per liter



Plasma Yield

9 -12% more plasma per collection^{3,4}



Productivity

16-minute reduction in door-to-door time^{3,4,5}



Safety

91% reduction in key quality events; 98% elimination of documentation errors^{3,4}




Donor Experience

93% affinity for NexSys PCS®; Improved donation experience^{3,4}

1) Plasma Protein Therapeutics Association (PPTA) 2) 2022 number of collections and centers are based on internal estimates 3) Representative in-market results, surveys 4) Based on baseline device, software configuration and donor population 5) Excludes Persona® Technology

Hospital Accelerates Revenue Growth, Expands Margins and Creates Inorganic Opportunities



Hemostasis Management



Expanding market penetration and establishing VET as standard of care

- Penetration into core clinical segments
- Increase in utilization through training and education
- Expansion of sales and clinical teams

Vascular Closure



VASCADE®,
VASCADE® MVP

Value creation driven by unique technology and commercial execution

- Focus on the Top 600 centers in the US, representing 67% of U.S. TAM (~89% of EP³)
- Increase in utilization
- Expansion of sales and clinical teams
- International expansion

1) Annual disposables market only in core markets 2) HIMSS Logic Database, internal analysis 3) Electrophysiology procedures 4) Only available in China 5) Not available in the U.S.

Innovation Agenda Focused on Core Value Drivers to Maximize Impact

Plasma



Plasma Yield



Productivity



Safety



Donor Experience

Hemostasis Management

- New clinical areas



Cardiology /
PCI



Postpartum
Hemorrhage



ICU /
COVID-19



Neurological
Interventions /
Stroke

- New Insights into Coagulation Status
- Ease of Use and Clinical Interpretation

Vascular Closure

- New products in small/mid-bore venous closure
- New arterial closure indications
- Large-bore closure

Arterial




Aortic
Valve



Aorta
Repair

Venous



Mitral
Repair




Leadless
Pacemaker

Inorganic Growth Supported by Proven M&A Approach and Track Record

Rigorous selection criteria:

- Strengthens our technology and leadership
- Enhances strategic position in core clinical segments
- Provides access to high-growth adjacent markets
- Produces attractive financial results



1) Acquisition of intellectual property assets related to TEG6s

Operational Excellence Program Improves Efficiency and Strengthens Business

SUMMARY OF THE PROGRAM

\$115M - \$125M¹

Gross savings from FY'20 through FY'25

~30%²

Net Savings

\$95-\$105M

One-time program costs^{2,3}

- Improves manufacturing and supply chain efficiency
- Diversifies and enhances access to critical resources
- Frees up funds for growth investments

1) Gross savings from the Operational Excellence Program at the end of FY'22 were \$71M. One-time program costs as of October 1, 2022 were \$62.3M. 2) Target net savings rate net of investments and inflationary headwinds 3) Includes restructuring charges over the course of the program. These charges are excluded from the adjusted results..

Capital Allocation Priorities Focused on Areas of Highest Return

CAPITAL CAPACITY
\$1.7B - \$2.1B¹



ORGANIC INVESTMENTS²

High impact and high ROI drivers



STRATEGIC M&A

High-growth leading products



SHARE BUYBACKS AND DEBT REPAYMENT

Return capital to stakeholders

1) Total cumulative capital capacity at the end of FY'26 after funding all initiatives included in long range plan 2) Incremental organic investments not funded in long range plan